TGR1202 in Relapsed and Refractory Follicular Lymphoma
Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the overall response rate (ORR) of TGR-1202 in R/R FL.
Secondary Objectives
- Determine the genetic and other novel biological markers that may be predictive of
response or resistance to TGR-1202 in patients with relapsed or refractory FL.
- Describe the Progression Free Survival (PFS), Duration of Response (DoR) after treatment
with TGR-1202.
- Describe the number of dose delays and dose reductions and other safety profile.